Global Molecular Point of Care (POC) Markets, Developments and Trends 2021-2022 & 2026
Dublin, May 10, 2022 (GLOBE NEWSWIRE) -- The "The Market and Future Potential for Molecular Point of Care (POC), 2022" report has been added to ResearchAndMarkets.com's offering.
The Market and Future Potential for Molecular Point of Care (POC), 2022 provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.
This report features a complete update on mPOC and COVID-19. It also discusses other growth areas. Molecular point of care or mPOC systems are designed to be faster than lab-based tests while more accurate than existing point of care systems. Development of new systems and menu expansion on existing lines is constant.
The analyst defines molecular point of care or mPOC as consisting of devices marketed to customers outside the reference lab that run PCR or other DNA and RNA testing on a device with a small footprint. mPOC systems tend to have a result time fast enough for an office visit or bedside consultation. These systems feature cartridges or reduced preparation steps and limited interpretation of test results.
Major IVD companies such as Abbott and Roche and Quidel compete, but there are many other and new entrants since our last reporting.
This was a subset of the testing industry still proving its merit to customers early last year, but certainly the ongoing COVID-19 pandemic has been an influence on the market, as we covered in recent reports. The ability to deliver rapid PCR results has put them in the right place with the right function at the right time.
Many trends are covered in the report, including menu expansion, disease statistics, the COVID-19 crisis, immunoassay competition and enhancement of those competitive POC systems, emerging markets, new journal studies about the efficacy of mPOC and other trends.
Key Topics Covered:
Chapter One: Executive Summary
Molecular Point of Care Market, 2021-2026
Where is Molecular Point of Care in 2021?
Molecular Point of Care Market Analysis
Market Observations
"Near-Patient" Molecular Systems Market
Current Trends
Molecular Point-of-Care Diagnostics Defined
Usage of Molecular Point of Care
Leading mPOC Platforms
Trends
Scope and Methodology
Chapter Two: Molecular Point-of-Care Market Development and Trends
COVID-19 and Molecular POC
CDC Initial Response, Long Term Situation
COVID-19's Unique Challenge
BARDA Directs Funding to mPOC
Recent Regulatory Developments
Consortia, Funding, Prizes
Deals
Advantages and Disadvantages of Molecular Point of Care
Justification: The Sensitivity/Specificity Argument
New Systems and Menu Expansion
Mesa Biotech Strep A Approval
Combination Tests Enter Market: SARS-CoV-2, Flu A, Flu B, and RSV
STI Continues to Be a Growth Area
Deals, Investment in mPOC Systems
Thermo Acquires Mesa Biotech
EU Researchers Awarded €3M to Develop POC Molecular Tests
Scope Fluidics AST System Sees Investment
China as a POC Market
Common Tests and Analytes in POC Diagnostics
Component Technologies of Molecular Point-of-Care Diagnostics
Microfluidics
qPCR
Microarrays
Isothermal Amplification
Test Automation
Primers and Probes
Detection
Next-Generation Sequencing
Molecular Diagnostics
Real-Time PCR (qPCR)
Isothermal Amplification Methods
Line Probe Assays
Next-Generation Sequencing
Applications and Potential Applications for Molecular Point-of-Care
Major Testing Applications for Molecular POC Diagnostics
Influenza
Reclassification of RIDTs
Hospital-Acquired Infections (HAIs)
Strep A
Respiratory Syncytial Virus (RSV)
Emerging Applications
Zika
Other Respiratory Infections
Group B Streptococcus
Human Papillomavirus
Herpes Simplex Virus
Vaginitis
Malaria
Other Tropical and Neglected Diseases
Cancer
European Device Regulations Nearing
Chapter Three: Market Analysis
Molecular Point of Care Market Analysis
"Near Patient Molecular" Market
Market Share Near Patient
Chapter Four: Company Profiles
Abbott Laboratories
Aidian Oy
Akonni Biosystems
binx health, inc.
Biocartis NV
bioMerieux SA
Cepheid (Danaher)
Molecular Healthcare-Acquired Infection (HAI) Testing
Molecular Sexual Health and Women's Health Testing
Molecular Critical Infectious Disease Testing
Molecular Oncology/Genetics Testing
Credo Diagnostics
Curetis NV (OpGen)
DiaSorin S.p.A
GenMark Diagnostics (Roche)
Greiner Bio-One GmbH
Meridian Bioscience, Inc.
Mesa Biotech, Inc. (Thermo)
QIAGEN NV
QuantuMDx Group
Quidel Corporation
Roche
Sekisui Diagnostics LLC
T2 Biosystems
For more information about this report visit https://www.researchandmarkets.com/r/bm4zrq
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
